• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

COPD - Articles and news items

epr-logo

Smartfish’s medical drink trial a success for COPD patients suffering from cachexia

Industry news / 20 September 2016 / Niamh Louise Marriott, Digital Content Producer

Cachexia is a condition of involuntary weight loss, undernourishment and a number of negative side-effects that can be seen in patients with Chronic obstructive pulmonary disease (COPD), as well as in cancer and in several severe inflammatory diseases, such as AIDS, congestive heart failure, tuberculosis and rheumatoid arthritis…

verona pharma

Verona secures funding commitments to help progress RPL554

Industry news / 20 June 2016 / Victoria White, Digital Content Producer

Verona Pharma has successfully secured funding commitments to raise gross proceeds of £44.7m through a conditional placing with new and existing investors…

RPL554

Positive Phase IIa study data for RPL554 in COPD

Industry news / 10 May 2016 / Victoria White, Digital Content Producer

RPL554 is a novel inhaled dual PDE3/PDE4 inhibitor with both bronchodilator and anti-inflammatory properties in the same molecule…

copd

Only minority of COPD patients may benefit from inhaled corticosteroids

Industry news / 8 April 2016 / Victoria White, Digital Content Producer

A new study shows that levels of eosinophils can help identify patients with COPD who may and may not benefit from the addition of ICS treatment…

RPL554

Verona Pharma announces positive headline data from RPL554 trial

Industry news / 15 March 2016 / Victoria White

The study met its primary objective, with nebulised RPL554 demonstrating a dose-dependent bronchodilator response in asthma patients…

RPL554

Do asthma and COPD exist? Experts call for a new approach to patient management

Industry news / 1 February 2016 / Victoria White

Defining a patient’s symptoms using the historical diagnostic labels of asthma and COPD is an outdated approach, according to experts…

Positive top-line results from the Japanese Phase II study of Traumakine® for the treatment of ARDS

AstraZeneca to acquire Takeda’s respiratory business

Industry news / 17 December 2015 / Victoria White

AstraZeneca is to acquire the core respiratory business of Takeda for $575 million, adding Daxas to its portfolio…

copd treatment market

Global COPD treatment market to hit $11.2 billion by 2021, says GBI Research

Industry news / 3 December 2015 / Victoria White

GBI Research says the market will rise at a steady CAGR of 2.9% from $9.2 billion in 2014 to $11.2 billion in 2021…

Ultibro-Breezhaler

Novartis announces new trial results for Ultibro Breezhaler in COPD

Industry news / 17 November 2015 / Victoria White

Once-daily Ultibro Breezhaler met its primary endpoint (non-inferiority) and also demonstrated superiority to twice-daily Seretide…

RPL554

Verona Pharma starts RPL554 Phase IIa combination study

Industry news / 14 October 2015 / Victoria White

Verona Pharma has announced that the first patients have been dosed in a Phase IIa combination study to evaluate the addition of RPL554 to standard reliever medications for COPD…

revefenacin

Phase 3 programme for revefenacin in COPD starts

Industry news / 14 September 2015 / Victoria White

The Phase 3 programme includes two replicate three-month efficacy studies and a single 12-month safety study…

copd

Results from the SUMMIT COPD CV survival study announced

Industry news / 9 September 2015 / Victoria White

For the primary endpoint of the study, the risk of dying on Relvar/Breo Ellipta 100/25mcg was 12.2% lower than on placebo over the study period, which was not statistically significant…

 

Webinar: Different thermal analysis techniques to measure the glass transitionWATCH NOW
+ +